CervoMed Inc
Research CervoMed Inc (CRVO) on Bullrun: market cap USD 35.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRVO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 35.84M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 6.57M
- Free cash flow-USD 6.92M
Valuation Snapshot
latest market cap is USD 35.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.01M | -USD 26.97M | -USD 23.45M | n/a | -5.22 | USD 8.24M | n/a | USD 18.22M |
| FY2024 | USD 9.74M | -USD 16.29M | -USD 16.53M | n/a | -3.25 | USD 9.00M | n/a | USD 39.20M |
| FY2023 | USD 7.14M | -USD 2.17M | n/a | n/a | -5.3 | USD 7.79M | n/a | USD 7.38M |
| FY2022 | USD 0 | -USD 5.80M | n/a | n/a | n/a | USD 4.09M | USD 12.41M | -USD 33.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 35.84M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 73.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 20.36M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 43.30M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.32M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 31.59M | n/a | n/a | n/a |
About CervoMed Inc
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CervoMed Inc's market cap?
CervoMed Inc's market capitalization is USD 35.84M.
What does CervoMed Inc do?
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.